Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers for congestive heart failure.

Matthew J Sorrentino1

  • 1University of Chicago, Pritzker School of Medicine, Department of Medicine, Section of Cardiology, 5841 S. Maryland Ave., MC 6080, Chicago, IL 60637, USA.

Comprehensive Therapy
|March 3, 2004
PubMed
Summary

Drug therapy targeting the renin-angiotensin and adrenergic nervous systems improves congestive heart failure (CHF) prognosis. Beta-adrenergic blocking drugs, previously avoided, now demonstrate improved survival rates in CHF patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Evolution from Hypertension to Heart Failure.

Heart failure clinics·2019
Same author

Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.

The pharmacogenomics journal·2019
Same author

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.

Pharmacogenetics and genomics·2018
Same author

Pharmacogenomics and cardiology: improving treatment with existing drugs.

Pharmacogenomics·2015
Same author

Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".

American journal of medical genetics. Part C, Seminars in medical genetics·2014
Same author

Bleeding risk prediction models in atrial fibrillation.

Current cardiology reports·2013

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) management traditionally focused on neurohormonal blockade.
  • Beta-adrenergic blocking drugs were historically contraindicated in CHF due to concerns about negative inotropic effects.

Purpose of the Study:

  • To evaluate the impact of drug therapies targeting the renin-angiotensin and adrenergic nervous systems on CHF prognosis.
  • To assess the role of beta-adrenergic blocking drugs in improving survival for CHF patients.

Main Methods:

  • Review of clinical studies and therapeutic guidelines.
  • Analysis of pharmacological interventions affecting the renin-angiotensin system.
  • Evaluation of outcomes associated with beta-adrenergic blockade in CHF populations.

Main Results:

  • Drug therapies targeting the renin-angiotensin and adrenergic nervous systems significantly improve CHF patient prognosis.
  • Beta-adrenergic blocking drugs, once contraindicated, are now proven to enhance survival in CHF.
  • Pharmacological modulation of these systems represents a cornerstone of modern CHF treatment.

Conclusions:

  • Targeted drug therapy offers substantial prognostic benefits for CHF patients.
  • Beta-adrenergic blockers are a vital component of CHF management, improving patient survival.
  • Understanding neurohormonal pathways is crucial for optimizing CHF treatment strategies.

Related Experiment Videos